Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II PET Imaging of MMR-Expressing Macrophages in NSCLC Using 68GaNOTA-Anti-MMR VHH2
2024-514138-19-00Phase 2Authorised
- Sponsor
- UZ Brussel
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-UZBRU-VHH2 in non-small cell lung cancer (NSCLC), sponsored by UZ Brussel. Primary endpoint: Immunohistological MMR score on excised tissue. Planned start Oct 2024; status: authorised.
02
Drugs
68Ga-UZBRU-VHH2
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514138-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514138-19-00.